Skip to main content

Table 3 The single and combined synergizing effects of ABT-737 on cell line viability and/or apoptosis

From: BH3-mimetics: recent developments in cancer therapy

Cancer Cell Type Combined Reduced Viability Apoptosis Ref
AML ex-vivo samples 5-azacytidine synergized [112]
Breast MDA-MB-231R irradiation synergized [113]
Breast T47D cisplatin synergized synergized [114]
Breast MCF-7, ZR-75-1, MDA-MB231 irradiation synergized [35]
Breast MDA-MB-435S VX-680 synergized [115]
Breast (TN) MDA-MB-231 docetaxel synergized [116]
CRC C26, HCT116, LS174T oxaliplatin synergized [117]
CRC HT-29, HCT116 celecoxib synergized [118]
Glioma LN229, LN18 bortezomib synergized [119]
HNSCC UM-22A, UM-22B, 1483 cisplatin/etopiside synergized [120]
Lung A549 and H460 lines perifosine synergized synergized [121]
Lung A549 and 95-D nedaplatin synergized [106]
Leukaemia HL-60, U-937, ML-1, MOLT-4 -single- reduced [122]
Leukaemia (T-cell) MOLT-4 resveratrol synergized [123]
Leukaemia HL-60 doxorubicin synergized [124]
Liver HuH-7, HepG2, BEL-7402, SMMC-7721 norcantharidin synergized [111]
Liver HepG2 curcumin synergized [125]
Melanoma A375, WM852c bortezomib synergized synergized [109]
NSCLC A549, H460, H1299, H358, H2009, H1703, H596 cisplatin synergized [126]
Oral MC-3, HSC-3 sorafenib synergized [127]
Osteosarcoma U-2OS cisplatin synergized [128]
Ovarian/Gastric SKOV-3, OVCAR-8, SGC-7901 epothilone B synergized [129]
Ovarian patient derived organoids naftopidil synergized [130]
Ovarian Ovcar-3, Igrov-1 pitavastatin synergized [131]
Ovarian A2780, cisA2780, IGROV-1, OVCAR, SK-OV-03, primary and xenograft carboplatin synergized synergized [132, 133]
Prostate DU 145, LNCaP and PC-3 ARC synergized [107]
Renal PV10, KRC/Y,A498, ACHN TRAIL synergized [134]
Retinoblastoma Y79, WERI-Rb -single- [108]
Thyroid FTC236, ML1, SW1736, HTh7 doxorubicin/gemcitabine synergized [135]
Uterine/Cervical SiHa, CaSki irradiation synergized [136]
Breast, Colon, Liver, Pancreatic SW480 and LIM1215, Huh-7 and HepG2, HPAC, MDA-MB-231 ARC synergized synergized [137]
Breast, Colon, Prostate MDA-MB-231, HT-29, DU145 methylseleninic acid synergized [110]
  1. The cancer types are highlighted in bold (left column), the evaluation of single therapy alone is highlighted by ‘-single-‘, non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: TN Triple Negative, CRC Colorectal cancer, HNSCC Head and Neck Squamous Cell Carcinoma, NSCLC Non-small cell lung cancer